Targeted delivery of thrombolytic enzymes
Although thrombolytic agents have been used for several decades in the treatment of thromboembolic conditions, there is an unmet need for the development of safer thrombolytic agents. The development of new molecules themselves may not be sufficient. This has sparked a growing interest in the design...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2021-03-01
|
| Series: | BioImpacts |
| Subjects: | |
| Online Access: | https://bi.tbzmed.ac.ir/PDF/bi-11-85.pdf |
| _version_ | 1819043895320772608 |
|---|---|
| author | Young M. Kwon |
| author_facet | Young M. Kwon |
| author_sort | Young M. Kwon |
| collection | DOAJ |
| description | Although thrombolytic agents have been used for several decades in the treatment of thromboembolic conditions, there is an unmet need for the development of safer thrombolytic agents. The development of new molecules themselves may not be sufficient. This has sparked a growing interest in the design of novel nanoscale drug carrier systems for the delivery of thrombolytic enzymes in an effort to address its fatal side effects. There are numerous proof-of-concept reports on such nanoscale systems that seek to capitalize on the pathophysiologic signatures of thrombosis as well as external biochemical/physical triggers. Although there may be a long road ahead before we have such new nanoscale therapeutics on the bedside, hopes remain high. |
| first_indexed | 2024-12-21T10:04:03Z |
| format | Article |
| id | doaj.art-e26725c8eeeb463ca7c558b440716661 |
| institution | Directory Open Access Journal |
| issn | 2228-5660 2228-5652 |
| language | English |
| last_indexed | 2024-12-21T10:04:03Z |
| publishDate | 2021-03-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | BioImpacts |
| spelling | doaj.art-e26725c8eeeb463ca7c558b4407166612022-12-21T19:07:52ZengTabriz University of Medical SciencesBioImpacts2228-56602228-56522021-03-01112858610.34172/bi.2021.15bi-23386Targeted delivery of thrombolytic enzymesYoung M. Kwon0Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University 3200 S. University Dr. Fort Lauderdale, FL 33328Although thrombolytic agents have been used for several decades in the treatment of thromboembolic conditions, there is an unmet need for the development of safer thrombolytic agents. The development of new molecules themselves may not be sufficient. This has sparked a growing interest in the design of novel nanoscale drug carrier systems for the delivery of thrombolytic enzymes in an effort to address its fatal side effects. There are numerous proof-of-concept reports on such nanoscale systems that seek to capitalize on the pathophysiologic signatures of thrombosis as well as external biochemical/physical triggers. Although there may be a long road ahead before we have such new nanoscale therapeutics on the bedside, hopes remain high.https://bi.tbzmed.ac.ir/PDF/bi-11-85.pdfthrombolyticstargeted deliverytpananocarriers |
| spellingShingle | Young M. Kwon Targeted delivery of thrombolytic enzymes BioImpacts thrombolytics targeted delivery tpa nanocarriers |
| title | Targeted delivery of thrombolytic enzymes |
| title_full | Targeted delivery of thrombolytic enzymes |
| title_fullStr | Targeted delivery of thrombolytic enzymes |
| title_full_unstemmed | Targeted delivery of thrombolytic enzymes |
| title_short | Targeted delivery of thrombolytic enzymes |
| title_sort | targeted delivery of thrombolytic enzymes |
| topic | thrombolytics targeted delivery tpa nanocarriers |
| url | https://bi.tbzmed.ac.ir/PDF/bi-11-85.pdf |
| work_keys_str_mv | AT youngmkwon targeteddeliveryofthrombolyticenzymes |